@roka
Re "This is a product already approved in several markets, so the results are to be expected"
I think you are drawing a reasonable conclusion. The market has long known about the previous success in other regions with the treatment of agvhd in children. It is also aware (or should be) of the size of the child market, and the fact that mesoblast have publicly stated it only works in a 40% subset of adults.
At a market cap well above $700 million with only a trickle of news coming in regarding partners for tier 1 treatments, I'd imagine many potential investors are happy to watch what happens.
- Forums
- ASX - By Stock
- MSB
- Ann: Key Day 100 Survival Results In P3 GvHD Trial
Ann: Key Day 100 Survival Results In P3 GvHD Trial, page-89
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.49 |
Change
0.000(0.00%) |
Mkt cap ! $1.701B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1472 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.45 | 6760 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10033 | 1.485 |
4 | 53700 | 1.480 |
1 | 770 | 1.475 |
3 | 62048 | 1.460 |
1 | 50000 | 1.455 |
Price($) | Vol. | No. |
---|---|---|
1.490 | 21995 | 1 |
1.505 | 24000 | 1 |
1.510 | 13666 | 2 |
1.515 | 99798 | 1 |
1.520 | 27250 | 3 |
Last trade - 09.51am 07/10/2024 (20 minute delay) ? |
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
MSB (ASX) Chart |
Day chart unavailable